{"id":386363,"date":"2020-11-22T03:32:25","date_gmt":"2020-11-22T08:32:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386363"},"modified":"2020-11-22T03:32:25","modified_gmt":"2020-11-22T08:32:25","slug":"shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/","title":{"rendered":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  22, 2020  (GLOBE NEWSWIRE) &#8212; Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (\u201cPraxis\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0PRAX).\u00a0\u00a0 Such investors are advised to contact Robert S. Willoughby at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mhlAWbegOHlOIfsbVSJmgy_lGTH0RSgNVqsdImQQcEsdS_9LOzOyKn61DU5GPR1CBFOEEtLIyWn3pQCW34wQ0DHCn2Xme-_-9Oa89YlarlE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>newaction@pomlaw.com<\/u><\/a> or 888-476-6529, ext. 7980.<\/p>\n<p align=\"justify\">The investigation concerns whether Praxis certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EKlAABA12EPUZu8KNTe5GaOgxSW1XHqI3z_Lqwl7hw77o9gYDexo3KYxvcqnp2WLOpoAg30VvsLqyCFuIvIBuEtF8OCZx9urTtEWPH75yeMU8GwJ99ZHY9ddgBWaQMzQsZDRAr2TMVbh9PnFX_APBz_JvHl9dwHQemhtzozqJ3I=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>[Click here for information about joining the class action]<\/u><br \/>\n          <\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"justify\">On November 9, 2020, post-market, Praxis announced receipt of \u201ca response from the U.S. Food and Drug Administration (\u201cFDA\u201d) on the Investigational New Drug (\u201cIND\u201d) submission for PRAX-114 for the treatment of major depressive disorder (\u2018MDD\u2019).\u201d\u00a0 Specifically, Praxis advised investors that \u201c[a]t the end of the 30-day IND review period, the FDA notified the Company that the IND has been placed on full clinical hold. \u00a0The FDA has not provided any reason for the clinical hold.\u201d\u00a0<\/p>\n<p align=\"justify\">On this news, Praxis\u2019s stock price fell $7.79 per share, or 21.78%, to close at $27.98 per share on November 10, 2020.<\/p>\n<p align=\"justify\">The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hGv2fe_h2Zf2eTmdJCWgaO5SkYYFUEIwkdTg_kPfdrPPcyOu2zL2xNKWON-_5Y6vkXyEMcKurU3gdqPBPZGmmZ1or2iJ4u5AcYAv3inLlgI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.pomerantzlaw.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>CONTACT:<br \/><\/strong>Robert S. Willoughby<br \/>Pomerantz LLP<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ePACyWiVD-nrk2hUx0zZ65l1pvUNFu1D9WS4QH51H5QLeaNFGZ1GvvCk0yROM2XHxSUoWK-jYzwo01wICc--qlf8uVJFg9MrKtRoVRX7_SM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>rswilloughby@pomlaw.com<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rLdEFZbURNoVjT1thOvIj5z3i-3SVYV7HLYHLgd8KVw3bcBBTExSmaTdFteJqC6Z1f-GCildIjk0NTwxFK6HoQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a>888-476-6529 ext. 7980<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/dd9832e6-dbdc-4e6a-8994-bf81bf456a2f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) &#8212; Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (\u201cPraxis\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0PRAX).\u00a0\u00a0 Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Praxis certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 [Click here for information about joining the class action] On November 9, 2020, post-market, Praxis announced receipt of \u201ca response from the U.S. Food and Drug Administration (\u201cFDA\u201d) on the Investigational New Drug (\u201cIND\u201d) submission for PRAX-114 for the treatment of major depressive disorder (\u2018MDD\u2019).\u201d\u00a0 Specifically, Praxis advised investors that \u201c[a]t the end of the 30-day IND &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386363","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) &#8212; Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (\u201cPraxis\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0PRAX).\u00a0\u00a0 Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Praxis certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 [Click here for information about joining the class action] On November 9, 2020, post-market, Praxis announced receipt of \u201ca response from the U.S. Food and Drug Administration (\u201cFDA\u201d) on the Investigational New Drug (\u201cIND\u201d) submission for PRAX-114 for the treatment of major depressive disorder (\u2018MDD\u2019).\u201d\u00a0 Specifically, Praxis advised investors that \u201c[a]t the end of the 30-day IND &hellip; Continue reading &quot;SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-22T08:32:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX\",\"datePublished\":\"2020-11-22T08:32:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/\",\"name\":\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=\",\"datePublished\":\"2020-11-22T08:32:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Market Newsdesk","og_description":"NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) &#8212; Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (\u201cPraxis\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0PRAX).\u00a0\u00a0 Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Praxis certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 [Click here for information about joining the class action] On November 9, 2020, post-market, Praxis announced receipt of \u201ca response from the U.S. Food and Drug Administration (\u201cFDA\u201d) on the Investigational New Drug (\u201cIND\u201d) submission for PRAX-114 for the treatment of major depressive disorder (\u2018MDD\u2019).\u201d\u00a0 Specifically, Praxis advised investors that \u201c[a]t the end of the 30-day IND &hellip; Continue reading \"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-22T08:32:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX","datePublished":"2020-11-22T08:32:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/","name":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=","datePublished":"2020-11-22T08:32:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDM0MSMzODM4ODY4IzIwMTc2NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc-prax-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. &#8211; PRAX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386363"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386363\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}